Adisseo(SH:600299) Soochow Securities·2025-12-04 14:02Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company is implementing a "dual pillar" strategy to enhance its global business development, focusing on solidifying its leadership in the methionine market while expanding its high-value specialty products [7] - The Quanzhou solid methionine project is progressing well, expected to be operational by 2027, which will support the company's global capacity optimization [7] - Revenue for the first three quarters of 2025 increased by 13.67% year-on-year, while net profit slightly decreased by 1.29% due to rising raw material costs and product price declines [7] Financial Projections - Total revenue is projected to reach 15,534 million yuan in 2024, with a year-on-year growth of 17.83%, and is expected to grow to 21,718 million yuan by 2027 [1][8] - The net profit attributable to the parent company is forecasted to be 1,204 million yuan in 2024, with a significant increase to 1,701 million yuan by 2027, reflecting a growth rate of 20.84% [1][8] - The earnings per share (EPS) is expected to rise from 0.45 yuan in 2024 to 0.63 yuan in 2027 [1][8] Market Position and Competitive Advantage - The company is positioned as a global leader in the methionine industry, with a strong focus on research and development to drive future growth [7] - The integration of resources from Sinochem in the Quanzhou project enhances cost competitiveness, leveraging location advantages [7]